These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

740 related items for PubMed ID: 26403380

  • 1. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.
    Isaacs JD, Cutolo M, Keystone EC, Park W, Braun J.
    J Intern Med; 2016 Jan; 279(1):41-59. PubMed ID: 26403380
    [Abstract] [Full Text] [Related]

  • 2. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S, Heap GA, Ahmad T, Kim H, Kwon T, Chowers Y.
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9 Suppl 1():27-34. PubMed ID: 26395532
    [Abstract] [Full Text] [Related]

  • 3. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
    Müller-Ladner U, Hong S, Oh C, Taylor P.
    Expert Rev Clin Immunol; 2015 Jan; 11 Suppl 1():S5-14. PubMed ID: 26395832
    [Abstract] [Full Text] [Related]

  • 4. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
    Schreiber S, Panés J, Kwon B, Hong S, Peyrin-Biroulet L.
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9 Suppl 1():5-15. PubMed ID: 26395530
    [Abstract] [Full Text] [Related]

  • 5. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S.
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9 Suppl 1():1-3. PubMed ID: 26395529
    [Abstract] [Full Text] [Related]

  • 6. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N.
    Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
    [Abstract] [Full Text] [Related]

  • 7. An updated review of infliximab biosimilar, CT-P13, in the treatment of immune-mediated inflammatory diseases.
    Wook Hong S, Kim YG, Ye BD.
    Immunotherapy; 2020 Jun; 12(9):609-623. PubMed ID: 32517574
    [Abstract] [Full Text] [Related]

  • 8. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P.
    Expert Rev Clin Immunol; 2015 Jun; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [Abstract] [Full Text] [Related]

  • 9. Biosimilars in the therapy of inflammatory bowel diseases.
    Hlavaty T, Letkovsky J.
    Eur J Gastroenterol Hepatol; 2014 Jun; 26(6):581-7. PubMed ID: 24722561
    [Abstract] [Full Text] [Related]

  • 10. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J, Kudrin A.
    Immunotherapy; 2015 Jun; 7(2):73-87. PubMed ID: 25713985
    [Abstract] [Full Text] [Related]

  • 11. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L, Peyrin-Biroulet L.
    Curr Med Chem; 2019 Jun; 26(2):270-279. PubMed ID: 27758715
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
    Reinisch W, Louis E, Danese S.
    Expert Rev Gastroenterol Hepatol; 2015 Jun; 9 Suppl 1():17-26. PubMed ID: 26395531
    [Abstract] [Full Text] [Related]

  • 14. A review of CT-P13: an infliximab biosimilar.
    McKeage K.
    BioDrugs; 2014 Jun; 28(3):313-21. PubMed ID: 24723086
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The use of biosimilars in paediatric inflammatory bowel disease.
    Jongsma MME, Vulto A, de Ridder L.
    Curr Opin Pediatr; 2017 Oct; 29(5):560-565. PubMed ID: 28692448
    [Abstract] [Full Text] [Related]

  • 17. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
    Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL.
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
    [Abstract] [Full Text] [Related]

  • 18. A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.
    Ha CY, Kornbluth A.
    Inflamm Bowel Dis; 2016 Oct; 22(10):2513-26. PubMed ID: 27564646
    [Abstract] [Full Text] [Related]

  • 19. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z, Gonczi L, Lakatos PL.
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.